Trial · NCT01905423
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
NCT01905423, Completed, Washington University School of Medicine; results first posted 2017-10-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis. Trials, record NCT01905423. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01905423
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
- NCT number
- NCT01905423
- Status
- Completed
- Enrollment
- 17,108 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Lymphatic Filariasis, Soil Transmitted Helminth Infections
- Interventions
- Albendazole (annual), Diethylcarbamazine (annual), Albendazole (semiannual), Diethylcarbamazine (semiannual)
- First posted
- 2013-07-23
- Last updated
- 2020-11-17
- Results first posted
- 2017-10-16
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood | 3 years | Microfilariae (filarial parasites) will be detected in blood smears by microscopy. Samples will be collected in annual and semiannual community surveys. Prevalence rates (a measure of the disease rates in the population sampled) are expressed as % positive for microfilaremia (having microfilaria in the blood). |
| Secondary | Prevalence of Positive Brugia Rapid Antifilarial Antibody Tests | 3 years | This outcome is reported as the frequency of participants with positive Brugia Rapid antifilarial antibody tests. Data was only collected at baseline and at year 3 for this outcome measure and no antibody data was collected for the Pekalongan study sites. |
| Secondary | Prevalence of Circulating Filarial Antigen in Blood as Determined by ICT Card Test | 3 years | Prevalence of filarial antigenemia (detected with the Binax Filariasis Now card test "ICT" card test) among the population surveyed. Prevalence data are expressed as %. |
| Secondary | Prevalence of Ascaris Infection | 2 Years | Prevalence of Ascaris infection is defined by the number of participants with any Ascaris worm eggs present in their stool sample as analyzed with microscopy. |
| Secondary | Prevalence of Hookworm Infection | 2 years | Prevalence of hookworm infection is defined by the number of participants with any hookworm eggs present in their stool sample as analyzed with microscopy. |
| Secondary | Prevalence of Trichuris Infection | 2 years | Prevalence of trichuris infection is defined by the number of participants with any trichuris worm eggs present in their stool sample as analyzed with microscopy. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood | 3 years | The Pekalongan study sites were dropped after the first year due to lower than expected prevalence of lymphatic filariasis infections. The overall number of participants analyzed for each group may be slightly less than the total sample size for that group due to the fact that not all data was collected for all participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Prevalence of Positive Brugia Rapid Antifilarial Antibody Tests | 3 years | This outcome data was only collected at baseline and at year 3 for Paga \& Pruda and no antibody data was collected at all for the Pekalongan study sites. The overall number of participants analyzed for each group may be less than the total sample size for that group due to the fact that not all data was collected for all participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Prevalence of Circulating Filarial Antigen in Blood as Determined by ICT Card Test | 3 years | This outcome data was not collected for Paga at year 3 or for Pekalongan sites after year 1 (Pekalongan study site was dropped completely after year 1). The overall number of participants analyzed for each group may be less than the total sample size for that group due to the fact that not all data was collected for all participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Prevalence of Ascaris Infection | 2 Years | The Pekalongan study sites were dropped after the first year. No soil transmitted helminth infection data was collected after year 2. The overall number of participants analyzed for each group may be slightly less than the total sample size for that group due to the fact that not all data was collected for all participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Prevalence of Hookworm Infection | 2 years | Hookworm prevalence was not analyzed for Pekalongan sites. Hookworm data was not collected after year 2 for any sites. The overall number of participants analyzed for each group may be slightly less than the total sample size for that group due to the fact that not all data was collected for all participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Prevalence of Trichuris Infection | 2 years | The Pekalongan study sites were dropped after the first year. No soil transmitted helminth infection data was collected after year 2. The overall number of participants analyzed for each group may be slightly less than the total sample size for that group due to the fact that not all data was collected for all participants. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group105
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood | Paga (1x Annual MDA) | Baseline (pre-MDA) | 54 | Participants | |
| Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood | Lewomada (1x Annual MDA) | Baseline (pre-MDA) | 36 | Participants | |
| Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood | Pruda (2x Annual MDA) | Baseline (pre-MDA) | 146 | Participants | |
| Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood | Pekalongan (1x Annual MDA) | Baseline (pre-MDA) | 46 | Participants | |
| Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood | Pekalongan (2x Annual MDA) | Baseline (pre-MDA) | 45 | Participants | |
| Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood | Paga (1x Annual MDA) | Year 1 | 11 | Participants | |
| Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood | Lewomada (1x Annual MDA) | Year 1 | 9 | Participants | |
| Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood | Pruda (2x Annual MDA) | Year 1 | 37 | Participants | |
| Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood | Pekalongan (1x Annual MDA) | Year 1 | 28 | Participants | |
| Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood | Pekalongan (2x Annual MDA) | Year 1 | 30 | Participants |
1 to 10 of 105Source ClinicalTrials.gov
See all 105 results by groupParticipant flow35
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Paga (1x Annual MDA) | 4,456 | |
| Overall Study | STARTED | Lewomada (1x Annual MDA) | 3,297 | |
| Overall Study | STARTED | Pruda (2x Annual MDA) | 4,111 | |
| Overall Study | STARTED | Pekalongan (1x Annual MDA) | 2,757 | |
| Overall Study | STARTED | Pekalongan (2x Annual MDA) | 2,487 | |
| Overall Study | Baseline | Paga (1x Annual MDA) | 1,443 | |
| Overall Study | Baseline | Lewomada (1x Annual MDA) | 722 | |
| Overall Study | Baseline | Pruda (2x Annual MDA) | 1,033 | |
| Overall Study | Baseline | Pekalongan (1x Annual MDA) | 1,482 | |
| Overall Study | Baseline | Pekalongan (2x Annual MDA) | 1,326 |
1 to 10 of 35Source ClinicalTrials.gov
See all 35 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals15
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Paga (Annual MDA) | 0 | 4,456 |
| Total, all-cause mortality | Lewomada (Annual MDA) | 0 | 3,297 |
| Total, all-cause mortality | Pruda (Semiannual MDA) | 0 | 4,111 |
| Total, all-cause mortality | Pekalongan (Annual MDA) | 0 | 2,757 |
| Total, all-cause mortality | Pekalongan (Semiannual MDA) | 0 | 2,487 |
| Total, other adverse events | Paga (Annual MDA) | 0 | 4,456 |
| Total, other adverse events | Lewomada (Annual MDA) | 0 | 3,297 |
| Total, other adverse events | Pruda (Semiannual MDA) | 0 | 4,111 |
| Total, other adverse events | Pekalongan (Annual MDA) | 0 | 2,757 |
| Total, other adverse events | Pekalongan (Semiannual MDA) | 0 | 2,487 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01905423
GET https://conductscience.org/api/trials/v1/NCT01905423/results?page=2